Aquestive Therapeutics Inc AQST
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-07-25 |
| Shares Out. | 125,470,000 |
| Website | aquestive.com/ ↗ |
| Phone | 19089411900 |
| Employees | 147 |
| Revenue | $14.4M |
| Gross Profit | $11.0M |
| Net Income | -$8.1M |
| Free Cash Flow | -$44.3M |
| Total Assets | $141.1M |
| Total Liabilities | $175.2M |
| Equity | -$34.1M |
About Aquestive Therapeutics Inc
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Aquestive Therapeutics Inc is a publicly traded company under the ticker symbol AQST on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)